Menopausal hormone therapy and pulmonary diseases

Area of Science:

• Reproductive endocrinology and pulmonary medicine intersection.
• Impact of sex steroids on respiratory system physiology and disease.

Background:

• Menopause involves decreased estrogen and progesterone, affecting respiratory health.
• Sex hormones influence lung development, immunity, airway function, and cancer pathways.
• Existing research on menopausal hormone therapy (MHT) and pulmonary diseases shows mixed results.

Purpose of the Study:

• To review and synthesize current evidence on MHT's effects on various pulmonary conditions.
• To guide clinical decision-making for women using MHT with existing or potential lung issues.

Main Methods:

• Comprehensive review of epidemiological studies, meta-analyses, and randomized trials.
• Analysis of data concerning MHT's association with asthma, COPD, pulmonary hypertension, sleep apnea, and lung cancer.
• Consideration of factors like estrogen formulation and route of administration.

Main Results:

• Asthma: Heterogeneous evidence, with some studies showing increased risk/exacerbations, others preserved lung function.
• COPD and Pulmonary Hypertension: Limited and inconsistent data; conflicting evidence for pulmonary hypertension with thrombotic risk considerations.
• Sleep Apnea: Potential modest benefits in select populations, but studies are methodologically diverse.
• Lung Cancer: Generally no clear increased incidence with MHT; potential survival benefits suggested in subgroups.

Conclusions:

• MHT's impact on pulmonary disease is complex and condition-specific.
• Individualized treatment plans are essential, considering patient symptoms, overall health risks, and MHT specifics.
• Further research is needed to clarify MHT's role in managing chronic pulmonary diseases.